Johannes vom Berg

List of Publications by Year
in descending order

31	1,620	759233 12	713466 21
papers	citations	h-index	g-index

34	34	34	3306
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. Oncogene, 2022, 41, 1507-1517.	5.9	3
2	Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer. , 2022, 10, e004044.		19
3	Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs. Cancers, 2021, 13, 785.	3.7	15
4	A ribonucleoprotein transfection strategy for CRISPR/Cas9â€mediated gene editing and single cell cloning in rainbow trout cells. Cell and Bioscience, 2021, 11, 103.	4.8	5
5	Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Science Translational Medicine, 2021, 13, eabc8188.	12.4	48
6	Enabling comprehensive optogenetic studies of mouse hearts by simultaneous opto-electrical panoramic mapping and stimulation. Nature Communications, 2021, 12, 5804.	12.8	6
7	DDRE-48. COMPARTMENT LOCKED IL-12 - INCREASED TISSUE RETENTION AND MINIMAL PERIPHERAL EXPOSURE ALLOW HIGHER TREATMENT EFFICACY AND TOLERABILITY IN LOCAL GLIOBLASTOMA THERAPY. Neuro-Oncology, 2021, 23, vi85-vi85.	1.2	0
8	Expression analysis data of BCL11A and Î³-globin genes in KU812 and KG-1Âcell lines after CRISPR/Cas9-mediated BCL11A enhancer deletion. Data in Brief, 2020, 28, 104974.	1.0	6
9	P09.10â€…Local immunotherapy of brain cancer harnessing high-retention Fc-fusion constructs. , 2020, , .		0
10	Enzymatic Dissociation Induces Transcriptional and Proteotype Bias in Brain Cell Populations. International Journal of Molecular Sciences, 2020, 21, 7944.	4.1	72
11	Microglia-Centered Combinatorial Strategies Against Glioblastoma. Frontiers in Immunology, 2020, 11, 571951.	4.8	17
12	Genetic variant PNPLA3 I148M accelerates fat accumulation in livers of mice with ASH/NASH via damping of PPAR alpha and PPAR gamma signalling pathways. Journal of Hepatology, 2020, 73, S175.	3.7	0
13	<scp>OMIPâ€065</scp>: Dog Immunophenotyping and Tâ€Cell Activity Evaluation with a 14â€Color Panel. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 1024-1027.	1.5	8
14	Delivery of Antibodies into the Murine Brain via Convection-enhanced Delivery. Journal of Visualized Experiments, 2019, , .	0.3	7
15	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. Clinical Cancer Research, 2019, 25, 5890-5900.	7.0	31
16	Bone marrow chimerasâ€”a vital tool in basic and translational research. Journal of Molecular Medicine, 2019, 97, 889-896.	3.9	9
17	Characterization of bispecific antibodies that drive synthetic agonistic receptor - transduced T cells to mediate specific and conditional therapy in human pancreatic cancer models. European Journal of Cancer, 2019, 110, S3.	2.8	0
18	Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease. European Journal of Pharmacology, 2019, 854, 398-405.	3.5	53

#	Article	IF	Citations
19	SCIDOT-06. TOWARDS EXCLUSIVELY LOCAL THERAPY OF GLIOBLASTOMA - ENGINEERING IL-12Fc WITH SUPERIOR TISSUE RETENTION AND MINIMAL SYSTEMIC EXPOSURE AFTER CNS ADMINISTRATION. Neuro-Oncology, 2019, 21, vi273-vi273.	1.2	0
20	Proof of concept and mode of action of a novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors. European Journal of Cancer, 2018, 92, S19.	2.8	0
21	Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor â€“ Transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models. European Journal of Cancer, 2018, 92, S20.	2.8	0
22	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Frontiers in Oncology, 2018, 8, 285.	2.8	89
23	SCDT-41. IN VIVO TESTING OF INTRACRANIAL DELIVERY OF RECOMBINANT HUMAN IL-12 AND IL-12Fc AND FUNCTIONAL ASSESSMENT ON HUMAN, PORCINE AND CANINE PERIPHERAL BLOOD MONONUCLEAR CELLS. Neuro-Oncology, 2017, 19, vi273-vi273.	1.2	0
24	The need for speed: how PD1-blockade only works if T cells are properly activated. Translational Cancer Research, 2017, 6, S1018-S1021.	1.0	0
25	T cell-specific inactivation of mouse CD2 by CRISPR/Cas9. Scientific Reports, 2016, 6, 21377.	3.3	11
26	New insights into IL-12-mediated tumor suppression. Cell Death and Differentiation, 2015, 22, 237-246.	11.2	373
27	In Vivo Imaging of Hypoxia-Inducible Factor Regulation in a Subcutaneous and Orthotopic GL261 Glioma Tumor Model Using a Reporter Gene Assay. Molecular Imaging, 2014, 13, 7290.2014.00029.	1.4	8
28	Intratumoral IL-12 combined with CTLA-4 blockade elicits T cellâ€“mediated glioma rejection. Journal of Experimental Medicine, 2013, 210, 2803-2811.	8.5	177
29	Inhibition of IL-12/IL-23 signaling reduces Alzheimer's diseaseâ€“like pathology and cognitive decline. Nature Medicine, 2012, 18, 1812-1819.	30.7	359
30	IL-12 initiates tumor rejection via lymphoid tissueâ€“inducer cells bearing the natural cytotoxicity receptor NKp46. Nature Immunology, 2010, 11, 1030-1038.	14.5	188
31	A Î²Pixâ€“Pak2a signaling pathway regulates cerebral vascular stability in zebrafish. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13990-13995.	7.1	107